Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
See our latest analysis for Palvella Therapeutics. Recent trading has been choppy, with a 1 day share price return of 5.10% decline and a 30 day share price return of 6.26% decline. However, a 90 day share price return of 25.69% and a very large 1 year total shareholder return suggest momentum has been building over the longer stretch as investors reassess Palvella Therapeutics' growth prospects and risk profile. If Palvella's sharp moves have caught your eye, this could be a useful moment to broaden your watchlist with other pharmaceutical opportunities using our screen for healthcare stocks With the shares around US$92 and analyst targets near US$184 alongside a very large 1 year total return, you have to ask: is Palvella still undervalued, or is the market already pricing in future growth? On simple valuation metrics, Palvella Therapeutics looks expensive, with a P/B of 28.3x at the last close of US$92.41 compared with peers on much lower multiples. P/B compares the mark
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.MarketBeat
- Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved TherapiesGlobeNewswire
- Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.MarketBeat
- Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical AffairsGlobeNewswire
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 1/12/26 - Form 8-K
- 1/2/26 - Form S-3
- 12/19/25 - Form 4
- PVLA's page on the SEC website